Introduction
============

The incidence of cancer in children younger than 15 years of age varies among countries worldwide. Despite dramatic improvements in therapeutics and early detection, cancer remains the second most common cause of childhood death in developed countries \[[@b1-crt-2015-290]\]. In some developed countries, such as Australia, Ireland, Switzerland, and the United States, childhood cancer incidence rates of 140-160 per million children have been reported \[[@b2-crt-2015-290]-[@b4-crt-2015-290]\]. According to a GLOBOCAN estimation of cancer rates in 2012, leukemia was the most common childhood malignancy worldwide, followed by malignancies of the brain and nervous system, non-Hodgkin lymphomas, renal tumors, and Hodgkin lymphomas. However, the rank and outcome of the most common cancer types varied among countries.

Cancer is also the second leading cause of childhood death in Korea. However, an epidemiologic study of cancer in children aged 0-14 years has never been conducted. We conducted the first nationwide study describing the incidence and survival of all childhood cancers in Korea.

Materials and Methods
=====================

1. Data sources
---------------

This study was approved by the Institutional Review Board (NCC 2015-0069). Data on childhood cancer incidence and survival in Korea were obtained from the Korea National Cancer Incidence database in the Korea Central Cancer Registry (KCCR).

The KCCR was initiated by the Korean Ministry of Health and Welfare in 1980 and collected cancer cases from more than 180 hospitals in Korea annually until 1998. These data represent 80%-90% of cancer incidence in Korea and have been collected on the entire Korean population since 1999 through a population-based cancer registry program \[[@b5-crt-2015-290]\].

The KCCR collects data on variables including age, sex, first diagnosis date, primary tumor site, morphology, method of diagnosis, and stage at diagnosis. KCCR statistics from 1999-2002 and 2003-2007 have been published in *Cancer Incidence in Five Continents* volumes IX and X (<http://ci5.iarc.fr/Default.aspx>), in which the completeness and validity of the incidence data were assessed.

The incidence rates of cancer in children aged 0-14 years who were diagnosed in 1999-2011 were calculated. For estimation of cancer survival, data on childhood cancer in 1993-2011 were obtained from the KCCR, and patients' vital status was followed up until December 31, 2012.

2. Case definition
------------------

To enable comparison with several previous studies of childhood cancer, the age group in this study was 0-14 years old \[[@b6-crt-2015-290]-[@b8-crt-2015-290]\]. Diagnoses were grouped into 12 main diagnostic groups and 47 subgroups according to the International Classification of Childhood Cancer, 3rd edition (ICCC-3) \[[@b9-crt-2015-290]\], which is based on the International Classification of Disease for Oncology, 3rd edition (ICD-O-3). The ICCC scheme, which is based on cancer topography and morphology, was specifically established for classification of tumors in children.

3. Statistical methods
----------------------

### 1) Incidence

Frequencies, percent distribution, crude incidence rates and annual percent change (APC) were computed by sex and age group (\< 1 year, 1-4 years, 5-9 years, and 10-14 years). Age-standardized incidence rates (ASRs) in males and females were estimated by the direct method using world standard population defined by the World Health Organization for age groups 0-14 years. The male/female ratio of the ASRs was also calculated. Cancer incidence trends were based on the APC, which was estimated using the following formula: 100×(e^β^--1), where β is the slope calculated from a linear regression of log ASRs in a calendar year (<http://seer.cancer.gov/csr/1975_2010/>).

### 2) Survival

The 5-year survival rate for each diagnostic group was analyzed based on relative survival for the following time periods: 1993-1995, 1996-2000, 2001-2005, 2006-2010, and 2007-2011. These time periods were chosen to enable direct comparison with earlier studies \[[@b10-crt-2015-290],[@b11-crt-2015-290]\]. The relative survival rates for each diagnostic group were calculated by dividing the observed survival by expected survival among comparable groups in the general population according to the Ederer II method. The survival rates were calculated by "complete analysis," which included "right-censored" patients. This analysis provided more up-to-date and precise survival rates in long-term survival, due to inclusion of the early survival experience of more recently recruited patients \[[@b12-crt-2015-290]\].

Trends in 5-year relative survival rates by time period were assessed using a relative excess risk model \[[@b13-crt-2015-290]\]. Statistical analyses were performed using SAS ver. 9.2 (SAS Institute Inc., Cary, NC).

Results
=======

1. Incidence
------------

A total of 15,113 cancer patients aged 0-14 years were diagnosed in 1999-2011, and the average annual incidence was 1,163 cases; 8,435 patients (55.8%) were males, and 6,678 (44.2%) were females. The age distribution was as follows: \< 1 year, 1,740 (11.5%); 1-4 years, 4,694 (31.1%); 5-9 years, 3,814 (25.2%); and 10-14 years, 4,865 (32.2%). The most common cancer was 'leukemias, myeloproliferative diseases, and myelodysplastic diseases' (group I), which accounted for 34.2% of all cancers in both sexes (males, 35.5%; females, 32.7%); 'lymphoid leukemia' (group I.a) represented almost one third of this group. 'Leukemias, myeloproliferative diseases, and myelodysplastic diseases' (group I), 'central nervous system (CNS) neoplasms' (group III), and 'lymphomas and reticuloendothelial neoplasms' (group II) accounted for more than half of all childhood cancer cases ([Fig. 1](#f1-crt-2015-290){ref-type="fig"}).

Between 1999 and 2011, the age-standardized incidence rate of all cancers was 144.0 and 124.9 per million for males and females, respectively. Higher cancer incidence was observed in males (male/female ratio, 1.2; p \< 0.05). The higher rate among males was due to a substantially higher incidence of 'lymphomas and reticuloendothelial neoplasms' (group II) (male, 16.9 per million; female, 9.6 per million). The highest incidence rate was observed in children \< 1 year old (277.3 per million), followed by those aged 1-4 years (164.9 per million), 10-14 years (111.7 per million), and 5-9 years (92.8 per million) ([Table 1](#t1-crt-2015-290){ref-type="table"}). The higher rate among children \< 1 year old was largely due to a substantially higher incidence rate of 'leukemias, myeloproliferative diseases, and myelodysplastic diseases' (group I) (63.7 per million), 'neuroblastoma and other peripheral nervous cell tumors' (group IV) (55.6 per million) and CNS neoplasms (group III) (26.1 per million).

Incidence trends showed a significant increase between 1999 and 2011 (APC: 2.4% per year in both sexes; 2.3% per year in males; 2.6% per year in females) ([Fig. 2](#f2-crt-2015-290){ref-type="fig"}). The incidence of most cancer types showed an increasing trend, with the exception of 'other and unspecified malignant neoplasms' (group XII) (APC, --7.4%; 95% confidence interval \[CI\], --12.2 to --2.3). There was a significant increase of APC in 'neuroblastoma and other peripheral nervous cell tumors' (group IV, 5.6%) and 'other malignant epithelial neoplasms and malignant melanomas' (group XI, 5.6%). However, in assessment by diagnostic group, the incidence of different cancer types varied between males and females. Among males, the highest increase in incidence was observed for 'other malignant epithelial neoplasms and malignant melanomas' (group XI) (APC, 6.1%; 95% CI, 1.1 to 11.3), followed by 'lymphomas and reticuloendothelial neoplasms' (group II) (APC, 4.8%; 95% CI, 2.4 to 7.2) and 'neuroblastoma and other peripheral nervous cell tumors' (group IV) (APC, 4.3%; 95% CI, 1.5 to 7.2). Among females, the highest increase in incidence was observed for 'neuroblastoma and other peripheral nervous cell tumors' (group IV) (APC, 7%; 95% CI, 4.9 to 9.3), followed by 'other malignant epithelial neoplasms and malignant melanomas' (group XI) (APC, 5%; 95% CI, --0.1 to 10.5) and 'soft tissue and other extraosseous sarcomas' (group IX) (APC, 4.3%; 95% CI, 1.1 to 7.6) ([Fig. 2](#f2-crt-2015-290){ref-type="fig"}).

2. Survival
-----------

The survival analysis comprised 20,523 children diagnosed with cancer in 1993-2011 (males, 11,644; females, 8,879). [Table 2](#t2-crt-2015-290){ref-type="table"} shows the 5-year relative survival rates and the number of cases in each of the five time periods (1993-1995, 1996-2000, 2001-2005, 2006-2010, and 2007-2011). In analysis by 12 main diagnostic group, 'leukemias, myeloproliferative diseases, and myelodysplastic diseases' (group I) and 'neuroblastoma and other peripheral nervous cell tumors' (group IV) showed the most marked improvements in survival, from 47.4% and 43.2% in 1993-1995 to 75.4% and 73.9% in 2007-2011, respectively. Survival rates for 'retinoblastoma' (group V) and 'other malignant epithelial neoplasms and malignant melanomas' (group XI) consistently exceeded 80%-90% for all periods measured. The lowest improvement in survival rate was observed for 'CNS neoplasms' (group III).

For all childhood cancers, the 5-year relative survival rate increased significantly, from 56.2% in 1993-1995 to 78.2% in 2007-2011 (p \< 0.05), with significant improvements in both males (from 56.7% in 1993-1995 to 77.7% in 2007-2011; p \< 0.05) and females (from 55.5% in 1993-1995 to 78.8% in 2007-2011) (p \< 0.05) and for all age groups tested ([Fig. 3](#f3-crt-2015-290){ref-type="fig"}). The improvement in the 5-year relative survival rate was slightly higher for females (23.3%) compared with males (21.0%). Among males, 5-year relative survival improved from 60.6% in 1993-1995 to 76.4% in 2007-2011 in children aged \< 1 year, from 54.9% to 82.9% in children aged 1-4 years, from 52.0% to 77.0% in children aged 5-9 years, and from 54.0% to 75.4% in children aged 10-14 years. Among females, 5-year relative survival improved from 48.6% in 1993-1995 to 73.5% in 2007-2011 in children aged \< 1 year, from 53.1% to 77.6% in children aged 1-4 years, from 55.0% to 76.6% in children aged 5-9 years, and from 56.1% to 80.3% in children aged 10-14 years ([Fig. 3](#f3-crt-2015-290){ref-type="fig"}).

Discussion
==========

Epidemiologic studies of childhood cancer can provide useful information. By understanding the age distribution of cancer, we can identify the likely period of initiation of various tumors, which can provide insights regarding their etiology. For example, childhood cancer incidence rate is the highest in infancy when embryonal neoplasms such as neuroblastoma predominate, indicating that many childhood cancers result from aberrations in early developmental processes \[[@b14-crt-2015-290]\]. Further, as children may be more vulnerable to environmental exposures because their organs are developing rapidly. The studies of childhood cancer etiology will provide useful information in terms of evaluating the risks and causal roles of environmental factors. In addition, survival data are useful in the development of surveillance programs for childhood cancer survivors, and survival trends can be used to evaluate progress in relation to treatment. However, there have been few nationwide epidemiological reports on childhood cancer providing reliable data over an extended period, particularly for Asian countries.

The KCCR is a national, population-based registry in South Korea. Annual incidence, survival, and prevalence rates of all cancers in Korea have been reported by the KCCR. In addition, a recent study provided epidemiological data on cancer in adolescents and young adults in Korea \[[@b11-crt-2015-290]\]. However, our study is the first to report cancer statistics for children younger than 15 years old in South Korea.

In comparison with other countries, our study found that the overall incidence of childhood cancer in South Korea was higher than that in other Asian countries such as China \[[@b15-crt-2015-290]\] and Thailand \[[@b16-crt-2015-290]\]. However, the incidence was lower than in countries in North America \[[@b2-crt-2015-290],[@b7-crt-2015-290]\] and Europe \[[@b17-crt-2015-290]\]. The reason for this worldwide variability in childhood cancer incidence is unclear. In general, low- and middle-income countries have lower rates of childhood cancer than developed countries, which can be explained in part by underdiagnosis and under-reporting in these countries \[[@b18-crt-2015-290]\]. In the United States, childhood cancer incidence differs between racial and ethnic groups; in 2006-2010, the incidence rate was lowest in an American Indian/native Alaskan group (111.7 per million) and highest in a non-Hispanic White group (178.2 per million) \[[@b19-crt-2015-290]\]. These racial/ethnic differences may be attributable to differences in genetic predisposition as well as environmental exposure \[[@b20-crt-2015-290]\].

In our study, the proportions of childhood cancer subtypes differed between age groups. In infants (aged \< 1 year), the most frequent cancer was neuroblastoma/ganglioneuroblastoma, followed by lymphoid leukemia. In children older than 1 year of age, lymphoid leukemia was the most common cancer.

The incidence rate of lymphoid leukemias was 28.3 per million in our study; in other countries, this ranged from 28 per million \[[@b17-crt-2015-290]\] to 40.8 per million \[[@b4-crt-2015-290]\]. In our study, incidence peaked around 3 years of age in both sexes (males, 55.7 per million; females, 60.4 per million). Similar peaks were also observed in data from white populations in the UK and United States in the early 20th century \[[@b21-crt-2015-290]\] and in recent studies conducted in Argentina \[[@b6-crt-2015-290]\]. The incidence of certain types of cancer is disproportionately high in some areas compared with overall incidence. For example, in sub-Saharan Africa, Burkitt lymphoma accounts for 25%-50% of all new childhood cancers, which can be explained by endemic Epstein-Barr virus \[[@b22-crt-2015-290]\].

In South Korea, incidence of childhood cancer increased by 2.4% annually from 1999 to 2011. It is possible that improvements in diagnostic technologies are leading to increased detection rates and thus increased incidence rates. Another possible reason for this increase is easy accessibility to hospital and treatment. Early studies in developed countries, based on data from the mid- to late-1970s, show increasing trends in incidence of childhood cancer \[[@b23-crt-2015-290],[@b24-crt-2015-290]\]; however, more recent data from the United States (1992-2004) \[[@b2-crt-2015-290]\], Australia (1983-2006) \[[@b4-crt-2015-290]\], and Canada (1992-2006) \[[@b7-crt-2015-290]\] show a plateau in childhood cancer incidence.

In this study, the incidence of most cancer subtypes showed an increasing trend; however, the incidence of 'other and unspecified malignant neoplasms' decreased annually (APC, --7.4%). This can be explained in part by improvements in diagnostic methods and in the quality of characterization, leading to more specific diagnoses. In the study of cancer incidence in Korean adolescents and young adults (aged 15-29 years), cancer incidence also increased over time, and the rate of increment was steeper (APC, 6.3%) \[[@b11-crt-2015-290]\].

In this study, the overall 5-year cancer survival rate was 78.2% for 2007-2011. This rate is lower than that of developed countries such as Italy \[[@b25-crt-2015-290]\] and the United States \[[@b19-crt-2015-290]\], but higher compared with developing countries in Asia such as China \[[@b15-crt-2015-290]\] and Thailand \[[@b16-crt-2015-290]\] (although the time periods are slightly different between these studies). These disparities may be caused by multiple factors, with a country's economic status being one contributor. In countries with a high economic status, children are more likely to have access to health insurance and to receive a timely diagnosis and high quality treatment and supportive care, and parents are more likely to have a high level of disease knowledge and adherence to therapy, all of which contribute to improved childhood cancer survival rates \[[@b20-crt-2015-290]\].

The current survival rate in South Korea is similar to that of the United States from 1995 to 1999 \[[@b23-crt-2015-290]\] and of Britain from 1998 to 2005 \[[@b8-crt-2015-290]\]. In the United States, the 5-year survival rate increased from 79.3% in 1995-1999 to 83.1% in 2004-2010 \[[@b19-crt-2015-290],[@b23-crt-2015-290]\]. This implies that improvements in the survival rate are possible in South Korea, and efforts should be made to achieve this.

In this study, survival rates varied between cancer subtype, increasing steadily from 1993-2011 for lymphoid leukemias and neuroblastoma, but with little change since 2005 for CNS tumors, soft tissue sarcoma, or osteosarcoma. Efforts to improve survival should be continued, especially for cancers with low survival rates such as CNS tumors.

In this study, it was not possible to describe long-term trends for incidence and survival due to the relatively short existence of the official population-based cancer registry in Korea. Another limitation is that information on cancer stage or treatment was not included.

Conclusion
==========

This study provides reliable information on incidence and survival trends for childhood cancers, providing a more comprehensive understanding of these cancers. The results from this study will be useful for professionals related with childhood cancer in the development of optimized healthcare services for childhood cancer patients and survivors.
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###### 

Number of cases, crude incidence rates, and age-standardized rates (ASR) per million of childhood cancers in Korea for the period 1999-2011

  Diagnostic group (ICCC-3)                                                       Total   Male ASR   Female ASR   M/F ratio[^a)^](#tfn2-crt-2015-290){ref-type="table-fn"}                                                                           
  ------------------------------------------------------------------------------- ------- ---------- ------------ ---------------------------------------------------------- ------- ------ ------- ------- -------- ------- ------- ------- ------- ----------------------------------------------------
  **All cancers**                                                                 1,740   277.3      4,694        164.9                                                      3,814   92.8   4,865   111.7   15,113   126.6   134.9   144.0   124.9   1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
   I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases        400     63.7       1,861        65.4                                                       1,491   36.3   1,424   32.7    5,176    43.4    46.4    50.9    41.4    1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    a. Lymphoid leukemias                                                         145     23.1       1,319        46.3                                                       929     22.6   734     16.9    3,127    26.2    28.3    31.0    25.4    1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    b. Acute myeloid leukemias                                                    116     18.5       330          11.6                                                       349     8.5    454     10.4    1,249    10.5    10.8    11.7    9.8     1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    c. Chronic myeloproliferative diseases                                        21      3.3        29           1.0                                                        62      1.5    93      2.1     205      1.7     1.7     2.1     1.3     1.6
    d. Myelodysplastic syndrome and other myeloproliferative diseases             54      8.6        67           2.4                                                        57      1.4    47      1.1     225      1.9     2.2     2.8     1.5     1.9[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    e. Unspecified and other specified leukemias                                  64      10.2       116          4.1                                                        94      2.3    96      2.2     370      3.1     3.4     3.3     3.5     0.9
   II. Lymphomas and reticuloendothelial neoplasms                                81      12.9       369          13.0                                                       498     12.1   673     15.5    1,621    13.6    13.4    16.9    9.6     1.8[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    a. Hodgkin disease                                                            \-      \-         12           0.4                                                        38      0.9    105     2.4     155      1.3     1.1     1.4     0.8     1.8[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    b. Non-Hodgkin lymphomas (except Burkitt lymphoma)                            15      2.4        118          4.1                                                        255     6.2    370     8.5     758      6.3     5.9     7.2     4.5     1.6[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    c. Burkitt lymphoma                                                           1       0.2        78           2.7                                                        104     2.5    95      2.2     278      2.3     2.3     3.6     0.9     4.0[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    d. Miscellaneous lymphoreticular neoplasms                                    55      8.8        125          4.4                                                        57      1.4    45      1.0     282      2.4     2.8     3.0     2.5     1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    e. Unspecified lymphomas                                                      10      1.6        36           1.3                                                        44      1.1    58      1.3     148      1.2     1.2     1.6     0.8     1.9[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
   III. CNS and miscellaneous intracranial and intraspinal neoplasms              164     26.1       566          19.9                                                       736     17.9   655     15.0    2,121    17.8    18.3    19.7    16.8    1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    a. Ependymomas and choroid plexus tumors                                      22      3.5        103          3.6                                                        61      1.5    31      0.7     217      1.8     2.1     2.1     2.0     1.0
    b. Astrocytomas                                                               24      3.8        88           3.1                                                        142     3.5    184     4.2     438      3.7     3.6     3.7     3.5     1.1
    c. Intracranial and intraspinal embryonal tumors                              57      9.1        230          8.1                                                        266     6.5    191     4.4     744      6.2     6.6     7.5     5.5     1.4[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    d. Other gliomas                                                              11      1.8        48           1.7                                                        110     2.7    97      2.2     266      2.2     2.2     2.1     2.2     1.0
    e. Other specified intracranial and intraspinal neoplasms                     7       1.1        12           0.4                                                        11      0.3    13      0.3     43       0.4     0.4     0.4     0.4     1.2
    f. Unspecified intracranial and intraspinal neoplasms                         43      6.9        85           3.0                                                        146     3.6    139     3.2     413      3.5     3.5     3.8     3.2     1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
   IV. Neuroblastoma and other peripheral nervous cell tumors                     349     55.6       565          19.8                                                       121     2.9    34      0.8     1,069    9.0     11.6    11.8    11.4    1.0
    a. Neuroblastoma and ganglioneuroblastoma                                     349     55.6       562          19.7                                                       117     2.8    28      0.6     1,056    8.8     11.5    11.7    11.4    1.0
    b. Other peripheral nervous cell tumors                                       \-      \-         3            0.1                                                        4       0.1    6       0.1     13       0.1     0.1     0.1     0.1     2.0[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
   V. Retinoblastoma                                                              141     22.5       255          9.0                                                        15      0.4    \-      \-      411      3.4     4.6     4.8     4.4     1.1[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
   VI. Renal tumors                                                               126     20.1       282          9.9                                                        90      2.2    27      0.6     525      4.4     5.5     5.4     5.7     0.9
    a. Nephroblastoma and other nonepithelial renal tumors                        121     19.3       261          9.2                                                        79      1.9    11      0.3     472      4.0     5.0     4.8     5.2     0.9
    b. Renal carcinomas                                                           \-      \-         5            0.2                                                        9       0.2    15      0.3     29       0.2     0.2     0.2     0.2     1.1
    c. Unspecified malignant renal tumors                                         5       0.8        16           0.6                                                        2       0.0    1       0.0     24       0.2     0.3     0.3     0.2     1.5[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
   VII. Hepatic tumors                                                            99      15.8       144          5.1                                                        45      1.1    45      1.0     333      2.8     3.4     3.6     3.3     1.1[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    a. Hepatoblastoma                                                             90      14.3       114          4.0                                                        23      0.6    7       0.2     234      2.0     2.6     2.8     2.3     1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    b. Hepatic carcinomas                                                         3       0.5        17           0.6                                                        20      0.5    37      0.8     77       0.6     0.6     0.6     0.6     1.0
    c. Unspecified malignant hepatic tumors                                       6       1.0        13           0.5                                                        2       0.0    1       0.0     22       0.2     0.2     0.2     0.3     0.6
   VIII. Malignant bone tumors                                                    13      2.1        71           2.5                                                        219     5.3    595     13.7    898      7.5     6.6     6.7     6.5     1.0
    a. Osteosarcomas                                                              \-      \-         20           0.7                                                        144     3.5    443     10.2    607      5.1     4.3     4.4     4.2     1.1[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    b. Chondrosarcomas                                                            \-      \-         \-           \-                                                         1       0.0    24      0.6     25       0.2     0.2     0.2     0.2     1.1
    c. Ewing tumors and related sarcomas of bone                                  9       1.4        30           1.1                                                        49      1.2    81      1.9     169      1.4     1.4     1.3     1.4     0.9
    d. Other specified malignant bone tumors                                      1       0.2        6            0.2                                                        9       0.2    18      0.4     34       0.3     0.3     0.2     0.3     0.7
    e. Unspecified malignant bone tumors                                          3       0.5        15           0.5                                                        16      0.4    29      0.7     63       0.5     0.5     0.5     0.5     1.1
   IX. Soft tissue and other extraosseous sarcomas                                96      15.3       221          7.8                                                        192     4.7    320     7.3     829      6.9     7.2     7.9     6.5     1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    a. Rhabdomyosarcomas                                                          42      6.7        151          5.3                                                        101     2.5    85      2.0     379      3.2     3.5     3.9     3.1     1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    b. Fibrosarcomas, peripheral nerve sheath tumors and other fibrous neopla는   23      3.7        13           0.5                                                        15      0.4    38      0.9     89       0.7     0.8     0.9     0.7     1.4[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    c. Kaposi sarcoma                                                             \-      \-         \-           \-                                                         \-      \-     \-      \-      \-       \-      \-      \-      \-      \-
    d. Other specified soft tissue sarcomas                                       24      3.8        41           1.4                                                        59      1.4    160     3.7     284      2.4     2.3     2.3     2.2     1.1
    e. Unspecified soft tissue sarcomas                                           7       1.1        16           0.6                                                        17      0.4    37      0.8     77       0.6     0.6     0.7     0.6     1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
   X. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads             178     28.4       200          7.0                                                        227     5.5    547     12.6    1,152    9.6     9.8     9.7     9.9     1.0
    a. Intracranial and intraspinal germ cell tumors                              11      1.8        9            0.3                                                        111     2.7    273     6.3     404      3.4     2.9     3.9     1.9     2.0[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    b. Malignant extracranial and extragonadal germ cell tumors                   103     16.4       43           1.5                                                        7       0.2    17      0.4     170      1.4     1.9     1.4     2.5     0.5
    c. Malignant gonadal germ cell tumors                                         59      9.4        142          5.0                                                        104     2.5    220     5.1     525      4.4     4.6     4.3     4.9     0.9
    d. Gonadal carcinomas                                                         1       0.2        2            0.1                                                        1       0.0    21      0.5     25       0.2     0.2     0.1     0.3     0.2
    e. Other and unspecified malignant gonadal tumors                             4       0.6        4            0.1                                                        4       0.1    16      0.4     28       0.2     0.2     0.2     0.3     0.8
   XI. Other malignant epithelial neoplasms and malignant melanomas               5       0.8        27           0.9                                                        121     2.9    479     11.0    632      5.3     4.5     3.1     6.1     0.5
    a. Adrenocortical carcinomas                                                  2       0.3        8            0.3                                                        5       0.1    1       0.0     16       0.1     0.2     0.0     0.3     0.1
    b. Thyroid carcinomas                                                         \-      \-         1            0.0                                                        45      1.1    242     5.6     288      2.4     2.0     0.8     3.3     0.2
    c. Nasopharyngeal carcinomas                                                  \-      \-         \-           \-                                                         5       0.1    35      0.8     40       0.3     0.3     0.4     0.1     4.1[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    d. Malignant melanomas                                                        2       0.3        9            0.3                                                        11      0.3    17      0.4     39       0.3     0.3     0.2     0.4     0.6
    e. Skin carcinomas                                                            \-      \-         4            0.1                                                        11      0.3    16      0.4     31       0.3     0.2     0.2     0.2     0.9
    f. Other and unspecified carcinomas                                           1       0.2        5            0.2                                                        44      1.1    168     3.9     218      1.8     1.5     1.4     1.7     0.8
   XII. Other and unspecified malignant neoplasms                                 88      14.0       133          4.7                                                        59      1.4    66      1.5     346      2.9     3.4     3.6     3.2     1.1[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}
    a. Other specified malignant tumors                                           3       0.5        25           0.9                                                        8       0.2    9       0.2     45       0.4     0.4     0.3     0.5     0.6
    b. Other unspecified malignant tumors                                         85      13.5       108          3.8                                                        51      1.2    57      1.3     301      2.5     3.0     3.3     2.7     1.2[^\*^](#tfn3-crt-2015-290){ref-type="table-fn"}

ICCC-3, International Classification of Childhood Cancer, 3rd edition; CR, crude incidence rate (per million), ASR, age standardized incidence rate (per million).

p \< 0.05.

M/F ratio=male ASR/female ASR.

###### 

Five-year relative survival rates for childhood cancer in Korea in 1993-2011 according to ICCC-3 diagnostic groups

  Diagnostic group (ICCC-3)                                                         Total   Change[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}                                                                  
  --------------------------------------------------------------------------------- ------- ------------------------------------------------------- ------- ------ ------- ------- ------- ------- ------- ------- ------------------------------------------------------
  **All cancers**                                                                   2,921   56.2                                                    5,441   64.1   5,563   72.3    5,496   77.2    5,481   78.2    22.0[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
   I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases          1,076   47.4                                                    1,944   58.4   1,999   68.2    1,875   74.9    1,883   75.4    28.0[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Lymphoid leukemias                                                           665     57.3                                                    1192    67.7   1215    77      1,164   80.6    1,156   81      23.7[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    b. Acute myeloid leukemias                                                      250     26.5                                                    504     41.8   494     50.9    424     58.9    435     59.7    33.2[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    c. Chronic myeloproliferative diseases                                          38      34.3                                                    81      47     66      66.7    84      88.5    88      86.1    51.8
    d. Myelodysplastic syndrome and other myeloproliferative diseases               6       100.4                                                   24      66.8   99      62.8    85      75.3    98      75.6    -24.8
    e. Unspecified and other specified leukemias                                    117     37.7                                                    143     44.1   125     56.9    118     66.4    106     69.1    31.4[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
   II. Lymphomas and reticuloendothelial neoplasms                                  252     64.1                                                    495     71.9   606     82.9    624     83.5    642     86.6    22.5[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Hodgkin disease                                                              26      84.8                                                    37      94.7   60      95.1    62      93.4    61      95.1    10.3
    b. Non-Hodgkin lymphomas (except Burkitt lymphoma)                              107     58.1                                                    246     69.6   286     78.4    310     74.9    300     78.8    20.7[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    c. Burkitt lymphoma                                                             18      72.4                                                    71      77.6   100     86.1    121     86      120     87.4    15.0
    d. Miscellaneous lymphoreticular neoplasms                                      28      46.6                                                    59      69.7   89      91.2    107     98.3    140     99.4    52.8[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    e. Unspecified lymphomas                                                        73      70                                                      82      64.8   71      76.2    24      91.8    21      90.6    20.6
   III. CNS and miscellaneous intracranial and intraspinal neoplasms                443     48.7                                                    775     46.7   798     54.7    759     57.3    734     59      10.3[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Ependymomas and choroid plexus tumors                                        27      55.7                                                    83      58     80      66.3    81      66.6    78      70.2    14.5
    b. Astrocytomas                                                                 104     54.9                                                    179     48.7   159     56.7    151     53.6    157     51.1    -3.8
    c. Intracranial and intraspinal embryonal tumors                                128     49.4                                                    251     55.1   302     57.4    275     60.9    278     60.4    11.0
    d. Other gliomas                                                                41      68.5                                                    73      46.7   88      45.5    134     43.9    119     49.7    -18.8[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    e. Other specified intracranial and intraspinal neoplasms                       6       33.5                                                    19      26.4   12      50.1    17      53      15      66.1    32.6
    f. Unspecified intracranial and intraspinal neoplasms                           137     36.6                                                    170     28.9   157     47.2    101     64.3    87      69.9    33.3[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
   IV. Neuroblastoma and other peripheral nervous cell tumors                       151     43.2                                                    373     54.9   354     70.3    364     71.5    360     73.9    30.7[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Neuroblastoma and ganglioneuroblastoma                                       145     43.6                                                    361     54.2   351     70      359     71.7    354     73.9    30.3[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    b. Other peripheral nervous cell tumors                                         6       33.4                                                    12      75.2   3       100.1   5       57.2    6       71.5    38.1
   V. Retinoblastoma                                                                103     90.7                                                    173     88.8   185     95.4    136     97.3    137     95.5    4.8[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
   VI. Renal tumors                                                                 112     78.1                                                    225     78.5   192     86.1    193     91.8    184     94.1    16.0[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Nephroblastoma and other nonepithelial renal tumors                          88      83.4                                                    193     80.6   180     86.9    178     92.2    170     93.6    10.2[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    b. Renal carcinomas                                                             5       40.1                                                    9       66.8   8       75.1    10      100.1   11      100.1   60.0[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    c. Unspecified malignant renal tumors                                           19      63.5                                                    23      65.5   4       75.1    5       60.1    3       100.1   36.6
   VII. Hepatic tumors                                                              60      48.5                                                    145     59.5   117     66.8    110     71.2    117     69.5    21.0[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Hepatoblastoma                                                               26      65.8                                                    79      72.5   87      76.1    86      77.7    93      76.1    10.3
    b. Hepatic carcinomas                                                           19      36.9                                                    42      35.8   24      33.4    20      43.4    20      38.9    2.0
    c. Unspecified malignant hepatic tumors                                         15      33.5                                                    24      58.6   6       66.8    4       75.1    4       75.1    41.6
   VIII. Malignant bone tumors                                                      184     57.2                                                    292     65.8   322     68.1    353     75.3    339     77.4    20.2[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Osteosarcomas                                                                132     55.4                                                    205     64.9   222     68.5    249     78.6    241     81.5    26.1[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    b. Chondrosarcomas                                                              4       75.2                                                    9       66.8   8       75.1    12      91.8    12      91      15.8
    c. Ewing tumors and related sarcomas of bone                                    16      50.1                                                    49      67.4   58      53.5    59      56.1    57      58.5    8.4
    d. Other specified malignant bone tumors                                        4       75.2                                                    6       66.8   13      100.1   13      66.4    10      55.2    -20.0
    e. Unspecified malignant bone tumors                                            28      64.4                                                    23      69.7   21      81      20      90.1    19      89.6    25.2
   IX. Soft tissue and other extraosseous sarcomas                                  146     57                                                      243     68.5   292     72.7    277     78.2    281     77.2    20.2[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Rhabdomyosarcomas                                                            70      48.7                                                    129     62.2   139     64.9    115     75.6    115     78.8    30.1[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    b. Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms   15      66.9                                                    20      85.2   37      75.9    32      84.2    31      79.4    12.5
    c. Kaposi sarcoma                                                               \-      \-                                                      2       50.1   \-      \-      \-      \-      \-      \-      \-
    d. Other specified soft tissue sarcomas                                         49      69.6                                                    64      73.6   92      78.3    102     82.5    106     79.3    9.7
    e. Unspecified soft tissue sarcomas                                             12      41.8                                                    28      75.2   24      91.8    28      65.8    29      60.8    19.0
   X. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads               196     79.4                                                    433     88.3   408     92.8    454     93.8    452     94.6    15.2[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Intracranial and intraspinal germ cell tumors                                44      68.3                                                    104     75.2   138     84.2    174     89      160     89.9    21.6[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    b. Malignant extracranial and extragonadal germ cell tumors                     31      55.2                                                    73      85.4   49      96.4    62      95.4    70      97.4    42.2[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    c. Malignant gonadal germ cell tumors                                           97      90.1                                                    228     95     201     97.7    200     98      206     98.5    8.4[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    d. Gonadal carcinomas                                                           8       75.2                                                    12      83.5   8       87.7    9       77.8    10      69.4    -5.8
    e. Other and unspecified malignant gonadal tumors                               16      94.2                                                    16      93.9   12      100.2   9       100.1   6       100.1   5.9
   XI. Other malignant epithelial neoplasms and malignant melanomas                 91      87                                                      214     83.8   177     84.8    284     94.8    290     93.8    6.8[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Adrenocortical carcinomas                                                    2       50.1                                                    4       50.2   6       66.8    8       71.7    6       77.9    27.8
    b. Thyroid carcinomas                                                           37      100.2                                                   90      96.8   77      100.1   134     100.1   148     100.1   -0.1
    c. Nasopharyngeal carcinomas                                                    10      100.3                                                   8       75.1   8       62.6    21      88.5    21      85.4    -14.9
    d. Malignant melanomas                                                          7       85.9                                                    10      70.2   7       71.5    22      86.5    23      91.1    5.2
    e. Skin carcinomas                                                              2       100.2                                                   12      91.8   6       100.1   10      100.1   12      100.1   -0.1
    f. Other and unspecified carcinomas                                             33      69.9                                                    90      73.4   73      72.7    89      92      80      86.2    16.3
   XII. Other and unspecified malignant neoplasms                                   107     52.6                                                    129     73.1   113     79      67      83.9    62      80.4    27.8[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    a. Other specified malignant tumors                                             6       16.7                                                    15      53.4   17      82.5    11      72.8    13      77      60.3[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}
    b. Other unspecified malignant tumors                                           101     54.7                                                    114     75.7   96      78.4    56      86.3    49      82.1    27.4[^\*^](#tfn6-crt-2015-290){ref-type="table-fn"}

ICCC-3, International Classification of Childhood Cancer, 3rd edition; CNS, central nervous system.

p \< 0.05 for trend.

Relative survival rate (%).
